NCT06581263

Brief Summary

The purpose of this study is to evaluate a novel VRP.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
10

participants targeted

Target at below P25 for all trials

Timeline
Completed

Started Jul 2025

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

August 27, 2024

Completed
7 days until next milestone

First Posted

Study publicly available on registry

September 3, 2024

Completed
11 months until next milestone

Study Start

First participant enrolled

July 22, 2025

Completed
8 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 22, 2026

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

March 22, 2026

Completed
Last Updated

March 25, 2026

Status Verified

March 1, 2026

Enrollment Period

8 months

First QC Date

August 27, 2024

Last Update Submit

March 24, 2026

Conditions

Psychedelic ExperiencesVirtual RealityHealthy Volunteer

Outcome Measures

Primary Outcomes (3)

  • Assess subjective experience of novel VRP (DeepDream) comparable to a standard dose of psychedelics.

    Subject experience will be assessed using the Altered States of Consciousness Rating Scale.

    Day 0 through Day 30

  • Assess subjective experience of novel VRP (DeepDream) comparable to a standard dose of psychedelics.

    Subject experience will be assessed using the Mystical Experience Questionnaire.

    Day 0 through Day 30

  • Assess subjective experience of novel VRP (DeepDream) comparable to a standard dose of psychedelics.

    Subject experience will be assessed using the Ego-Dissolution Inventory.

    Day 0 through Day 30

Secondary Outcomes (1)

  • Assess the incidence of VRP adverse effects, principally virtual reality sickness (VRS) and neck and upper back pain.

    Day 0 through Day 30

Study Arms (1)

Healthy Volunteer

Device: Meta Quest 3

Interventions

Meta Quest 3DEVICE

Meta Quest 3 is a virtual reality headset device

Healthy Volunteer

Eligibility Criteria

Age21 Years - 65 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Healthy volunteers

You may qualify if:

  • Ability to provide informed consent
  • No history or current DSM-V diagnosis

You may not qualify if:

  • Unstable medical conditions

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Yale University School of Medicine

New Haven, Connecticut, 06510, United States

Location

Study Officials

  • Anahita Bassir Nia, MD

    Yale University

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
CASE CROSSOVER
Time Perspective
OTHER
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Assistant Professor of Psychiatry

Study Record Dates

First Submitted

August 27, 2024

First Posted

September 3, 2024

Study Start

July 22, 2025

Primary Completion

March 22, 2026

Study Completion

March 22, 2026

Last Updated

March 25, 2026

Record last verified: 2026-03

Locations

US(1)